Pricing Log in Create free account
Saturday 17 October 2026 Export BCYC’s income statement to Excel — free account

Bicycle Therapeutics PLC Sponsored ADR

BCYC Healthcare Biotechnology

Bicycle Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $72.6 million, up 105.8% from fiscal 2024. In the quarter to June 2026, revenue fell 78.5%, EPS grew 36.8% and free cash flow grew 32.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

3.46 0.14 −3.89%
Market cap
$181.4M
P/E
0.0×
Fwd P/E
−1.8×
Dividend yield
—
F-score
2/9
Altman Z
0.99
Beneish M
−1.37
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.46
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — 6 — — 5 — — 5 — — 1
Insider Ownership 34.96%

Capital & Financial Ratios $m

Market Cap 181.37
Revenue 61.21
Net Income (190.41)
Free Cash Flow (208.28)
Net Debt (510.05)
Current Ratio 12.08 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (1.76) (negative: loss-making)
P/S ratio 3.95
P/B ratio 0.47
Past 5Y EPS Growth —
This Y EPS Growth 23.13% (at or above 15%: strong)
Next Y EPS Growth 4.49%
Next Y revenue growth (75.85%) (below 0%: weak)
Next 5Y EPS Growth 6.86%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −4.0×, against a ten-year median of 14.1×; over the ten years it ranged from −11.4× in 2025 to 95.7× in 2021.
P/S against its own 10 years 1.50%
10-year low 10-year high
P/B against its own 10 years 0.22%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 526 880 628 510
Receivables 24 36 36 47
Inventory — — — —
Other — — — —
562 929 683 575
2023 2024 2025 Q'26
Payables 13 16 10 6
ST’ Debt — — — —
Other — — — —
70 67 57 48

Compound Annual Growth %

10y 5y 3y
Sales — 47.52% 71.21%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 44.91% 31.09%

Revenue $m

Mar Jun Sep Dec Year
’26 1 1 — — —
’25 10 3 12 48 73
’24 20 9 3 4 35
’23 5 11 5 5 27
’22 4 4 3 3 14
’21 2 2 4 4 12
’20 1 2 4 4 10
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (66) (50) — — —
’25 (86) (73) (71) (19) (250)
’24 (71) (45) (40) (9) (165)
’23 (46) 34 (1) (47) (61)
’22 (26) (24) (6) (30) (86)
’21 (14) (12) 22 (10) (15)
’20 21 (12) (10) (17) (18)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (67) (50) — — —
’25 (87) (73) (72) (20) (252)
’24 (71) (45) (40) (10) (166)
’23 (49) 34 (2) (47) (64)
’22 (31) (33) (9) (32) (105)
’21 (14) (13) 22 (12) (17)
’20 21 (13) (10) (17) (19)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.87) (0.72) — — —
’25 (0.88) (1.14) (0.85) (0.29) (3.16)
’24 (0.62) (0.77) (0.74) (0.75) (2.90)
’23 (1.30) (1.41) (1.26) (1.16) (5.08)
’22 (0.93) (0.90) (0.96) (1.01) (3.80)
’21 (0.73) (0.74) (0.59) (0.63) (2.67)
’20 (0.63) (0.67) (0.52) (0.83) (2.66)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — 6.24 9.16 18.00 12.08 12.54 12.17 6.03

Analyst estimates 2026–2028

Powerpack
High — — — 14.91 22.71 62.08 60.80 31.91 28.67 15.47
People
People Employees — — 61 72 87 119 236 284 305 288
Revenue/emp, $m — 0.00 0.12 0.19 0.12 0.10 0.06 0.09 0.12 0.25
Income, $m
Income, $m Revenue — 2 7 14 10 12 14 27 35 73
Gross margin, % 0.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT (14) (16) (22) (31) (52) (68) (114) (179) (174) (219)
EBT margin, % 0.00 (790.39) (311.69) (223.62) (497.92) (585.47) (789.88) (664.32) (492.69) (301.45)
Net income (14) (16) (22) (31) (51) (67) (113) (181) (169) (219)
Depreciation 0 0 1 1 1 1 4 7 7 6
Per share, $
Per share, $ Revenue 0.00 6.18 16.26 1.25 0.54 0.47 0.49 0.76 0.61 1.05
Earnings (0.76) (48.81) (49.78) (2.77) (2.66) (2.67) (3.80) (5.08) (2.90) (3.16)
Cash flow (0.54) (4.25) (59.42) (2.59) (0.93) (0.59) (2.90) (1.70) (2.83) (3.60)
Capex 0.00 (3.34) (2.70) (0.14) (0.06) (0.08) (0.64) (0.08) (0.02) (0.03)
Free cash flow (0.54) (7.59) (62.12) (2.73) (0.99) (0.67) (3.54) (1.79) (2.85) (3.64)
Book value 0.38 (141.65) (159.09) 8.44 4.99 13.82 9.13 10.42 13.62 8.80
Shares, m 21 0 0 11 19 25 30 36 58 69
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — 0.93 0.93 7.55 33.08 130.42 61.52 24.33 23.10 6.76
P/B — 0.00 0.00 1.12 3.60 4.41 3.29 1.77 1.03 0.80
EV/Sales — (4.61) (4.61) 1.01 21.47 95.67 40.39 6.13 (1.30) (1.61)
EV/FCF — 1.95 1.95 (0.46) (11.75) (66.52) (5.56) (2.60) 0.28 0.46
Cash, $m
Cash, $m Operating cash flow (11) (1) (26) (29) (18) (15) (86) (61) (165) (250)
Capex 0 (1) (1) (2) (1) (2) (19) (3) (1) (2)
Free cash flow (11) (3) (27) (30) (19) (17) (105) (64) (166) (252)
Balance, $m
Balance, $m Working capital 7 62 68 95 133 422 316 492 861 626
Total debt — — — 1 15 30 30 31 — —
Net debt (9) (68) (63) (91) (121) (409) (309) (496) (880) (628)
Shareholders’ equity 8 (47) (70) 93 95 346 271 371 793 610
Returns, %
Returns, % ROA (31.48) (37.88) (28.07) (31.91) (37.60) (20.85) (25.32) (35.92) (21.78) (26.15)
ROIC 0.00 0.00 0.00 (704.84) 0.00 0.00 0.00 0.00 0.00 0.00
ROE 33.37 40.16 37.34 (261.92) (54.08) (30.25) (36.53) (56.31) (29.04) (31.21)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Bicycle Therapeutics PLC Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
YARW Yarrow Bioscience, Inc $188.8M — (loss-making) — (loss-making) +40.58% (above 0%: growing) n/m +81.56% (above 0%: growing) 100.00% (3,197.94%) Compare
TRDA Entrada Therapeutics, Inc. $186.1M — (loss-making) — (loss-making) −53.95% (below 0%: shrinking) n/m −9.10% (below 0%: shrinking) 100.00% (5,007.02%) Compare
UPB Upstream Bio, Inc. $184.6M — (loss-making) — (loss-making) −17.50% (below 0%: shrinking) n/m +9.33% (above 0%: growing) 100.00% (5,480.98%) Compare
ELDN Eledon Pharmaceuticals, Inc. $184.5M — (loss-making) — — n/m −28.02% (below 0%: shrinking) 0.00% 0.00% Compare
SION Sionna Therapeutics, Inc. $184.5M — (loss-making) — — n/m −22.40% (below 0%: shrinking) — 0.00% Compare
ACOG Alpha Cognition Inc. $184.0M — (loss-making) — +267.56% (above 0%: growing) n/m −109.25% (below 0%: shrinking) 94.80% (127.29%) Compare
BCYC Bicycle Therapeutics PLC Sponsored ADR $181.4M — (loss-making) — (loss-making) −78.46% (below 0%: shrinking) n/m +31.95% (above 0%: growing) 100.00% (8,673.93%)
PEPG PepGen, Inc. $175.2M — (loss-making) — — n/m +33.02% (above 0%: growing) 0.00% 0.00% Compare
ORMP Oramed Pharmaceuticals Inc. $173.9M 1.0× — (loss-making) +193.26% (above 0%: growing) +493.75% (above 0%: growing) +94.29% (above 0%: growing) 0.65% 0.00% Compare
Median of peers $184.5M — — +40.58% — +0.11% 94.80% (63.64%)

All 614 Biotechnology stocks →

Bicycle Therapeutics PLC Sponsored ADR (BCYC) key facts

  • Strength: Bicycle Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $72.6 million, up 105.8% from fiscal 2024.
  • Bicycle Therapeutics PLC Sponsored ADR (BCYC) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
  • As of October 16, 2026, BCYC traded at $3.46, a market capitalization of $181.4 million.
  • Return on equity was −31.2% and debt-to-equity 0.00.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 0.99 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/BCYC · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com